Kadir Demir
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Kadir Demir has a total of 76 co-authors. Here are the top co-authors by number of shared publications:
- Aslı Çifcibaşı Örmeci
Division of Gastroenterohepatology, Department of Internal Medicine, Istanbul University Istanbul Faculty of Medicine, Istanbul, Turkiye
17 shared publications - Sabahattin Kaymakoglu
Division of Gastroenterohepatology, Department of Internal Medicine, Istanbul University Istanbul Faculty of Medicine, Istanbul, Turkiye
15 shared publications - Bilger Çavuş
Division of Gastroenterohepatology, Department of Internal Medicine, Istanbul University Istanbul Faculty of Medicine, Istanbul, Turkiye
14 shared publications - Fatih Beşışık
Division of Gastroenterohepatology, Department of Internal Medicine, Istanbul University Istanbul Faculty of Medicine, Istanbul, Turkiye
14 shared publications - Filiz Akyüz
Department of Gastroenterology, İstanbul University İstanbul Faculty of Medicine, İstanbul, Türkiye
12 shared publications - Ibrahim Volkan Senkal
Division of Gastroenterology, Department of Internal Medicine, İstanbul Faculty of Medicine, İstanbul University, İstanbul, Turkey
6 shared publications
Latest Publications
- 15 May 2026
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 138 (4) , 479-486
Time of first diagnosis in liver cirrhosis: what has changed over time from etiology to stage of disease?
It was aimed to investigate the characteristics of cirrhosis etiology, stage at diagnosis, diagnostic methods, and complications with a 1-decade interval. The clinical and demographic characteristics of patients with cirrhosis at the time of diagnosis at a tertiary university hospital between 2005-2009 (first period) and 2019-2023 (second period) were retrospectively investigated. In total, 1311 patients were diagnosed with cirrhosis, of which 857 (65.4%) were men. Seven hundred and ninety-eight (60.9%) were diagnosed in the first period. Six hundred and ninety (52.6%) patients were decompensated at diagnosis. Child Turcotte Pugh score was more common in the second period. MELD-Na score was higher in the first period (p = 0.026). The presentation rate with decompensation was higher in the first period (p = 0.009). In the first period, 211 (26.4%), and in the second period, 134 (26.1%) patients were diagnosed in the emergency department. The others were diagnosed in the outpatient clinic. There was no difference in the conditions for diagnosing between periods (p = 0.898). The causes of cirrhosis were, in order, 22.6% HBV, 19.7% MASLD, 18.9% cryptogenic, 13.1% ALD, 10.1% HCV, 7.7% autoimmune liver diseases, 4% HDV, 2.1% other causes, and 1.8% genetic diseases. In the second period, the frequency of cirrhosis caused by viral etiologies decreased (p < 0.05), and the frequency of MASLD and ALD increased (p < 0.05). Over the past decade, viral factors in the etiology of cirrhosis have gradually decreased, MASLD and ALD have progressively increased. While patients were detected more in compensated states, a significant portion of patients are still diagnosed in the decompensated stage and in emergency clinics.
- 15 May 2026
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 138 (4) , 479-486
Time of first diagnosis in liver cirrhosis: what has changed over time from etiology to stage of disease?
It was aimed to investigate the characteristics of cirrhosis etiology, stage at diagnosis, diagnostic methods, and complications with a 1-decade interval. The clinical and demographic characteristics of patients with cirrhosis at the time of diagnosis at a tertiary university hospital between 2005-2009 (first period) and 2019-2023 (second period) were retrospectively investigated. In total, 1311 patients were diagnosed with cirrhosis, of which 857 (65.4%) were men. Seven hundred and ninety-eight (60.9%) were diagnosed in the first period. Six hundred and ninety (52.6%) patients were decompensated at diagnosis. Child Turcotte Pugh score was more common in the second period. MELD-Na score was higher in the first period (p = 0.026). The presentation rate with decompensation was higher in the first period (p = 0.009). In the first period, 211 (26.4%), and in the second period, 134 (26.1%) patients were diagnosed in the emergency department. The others were diagnosed in the outpatient clinic. There was no difference in the conditions for diagnosing between periods (p = 0.898). The causes of cirrhosis were, in order, 22.6% HBV, 19.7% MASLD, 18.9% cryptogenic, 13.1% ALD, 10.1% HCV, 7.7% autoimmune liver diseases, 4% HDV, 2.1% other causes, and 1.8% genetic diseases. In the second period, the frequency of cirrhosis caused by viral etiologies decreased (p < 0.05), and the frequency of MASLD and ALD increased (p < 0.05). Over the past decade, viral factors in the etiology of cirrhosis have gradually decreased, MASLD and ALD have progressively increased. While patients were detected more in compensated states, a significant portion of patients are still diagnosed in the decompensated stage and in emergency clinics.
- 9 February 2026
- Published by Istanbul University in İstanbul Tıp Fakültesi Dergisi
- Vol. 89 (1) , 23-30
PRIMARY GASTROINTESTINAL SYSTEM LYMPHOMA: ANALYSIS OF EIGHT PATIENTS IN A SINGLE-CENTER COHORT
Objective: This study aimed to investigate the features of eight patients diagnosed with primary gastrointestinal system lymphoma.Materials and Methods: The features of patients diagnosed with primary gastrointestinal system lymphoma between 2021 and 2024 at the İstanbul Faculty of Medicine, Department of Internal Medicine, Division of Gastroenterohepatology, were retrospectively investigated.Results: Of the eight patients, 5 (62.5%) were male. The mean age was 55.1±18.8 (28–70) years. 4 (50%) patients had diabetes mellitus, one had Crohn's disease, one had decompensated cirrhosis, and one had compensated cirrhosis. The most common complaint of patients was stomachache. One of the patients who presented with stomachache had volvulus, one had ascites infection, and one had acute pancreatitis. Intestinal T-cell lymphoma was diagnosed in two, Burkitt lymphoma (BL) in two, Hodgkin lymphoma in one, mantle cell lymphoma (MCL) in one, follicular lymphoma in one and B-cell non-Hodgkin's lymphoma in one patients. The diagnosis of 4 (50%) patients was made by surgical resection, 3 (37.5%) patients were diagnosed by endoscopic biopsy and 1 (12.5%) patient was computerized by ascites fluid cytological examination and endoscopic biopsy. Four patients had lymphoma involvement in the small intestine, one patient had stomach, one patient had stomach and small intestine, one patient had spleen, and one patient had stomach, small intestine, and pancreas involvement.Conclusion: Primary gastrointestinal system lymphomas are rare diseases that can present in a wide age range and very different clinical presentations, and the small intestine was the most common involvement site in our cohort.
- 9 February 2026
- Published by Istanbul University in İstanbul Tıp Fakültesi Dergisi
- Vol. 89 (1) , 23-30
PRIMARY GASTROINTESTINAL SYSTEM LYMPHOMA: ANALYSIS OF EIGHT PATIENTS IN A SINGLE-CENTER COHORT
Objective: This study aimed to investigate the features of eight patients diagnosed with primary gastrointestinal system lymphoma.Materials and Methods: The features of patients diagnosed with primary gastrointestinal system lymphoma between 2021 and 2024 at the İstanbul Faculty of Medicine, Department of Internal Medicine, Division of Gastroenterohepatology, were retrospectively investigated.Results: Of the eight patients, 5 (62.5%) were male. The mean age was 55.1±18.8 (28–70) years. 4 (50%) patients had diabetes mellitus, one had Crohn's disease, one had decompensated cirrhosis, and one had compensated cirrhosis. The most common complaint of patients was stomachache. One of the patients who presented with stomachache had volvulus, one had ascites infection, and one had acute pancreatitis. Intestinal T-cell lymphoma was diagnosed in two, Burkitt lymphoma (BL) in two, Hodgkin lymphoma in one, mantle cell lymphoma (MCL) in one, follicular lymphoma in one and B-cell non-Hodgkin's lymphoma in one patients. The diagnosis of 4 (50%) patients was made by surgical resection, 3 (37.5%) patients were diagnosed by endoscopic biopsy and 1 (12.5%) patient was computerized by ascites fluid cytological examination and endoscopic biopsy. Four patients had lymphoma involvement in the small intestine, one patient had stomach, one patient had stomach and small intestine, one patient had spleen, and one patient had stomach, small intestine, and pancreas involvement.Conclusion: Primary gastrointestinal system lymphomas are rare diseases that can present in a wide age range and very different clinical presentations, and the small intestine was the most common involvement site in our cohort.
- Open Access
- 22 October 2025
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Gastroenterology
- Vol. 37 (3) , 301-309
Maternal and Fetal Outcomes of Pregnancies in Wilson’s Disease: A Single-Centre Real-Life Experience
Background/Aims: This study aims to investigate the fetal outcomes and pregnancy course in patients with Wilson’s disease (WD). Materials and Methods: A total of 54 female patients with a diagnosis of WD and a history of pregnancy between 1985 and 2021 were retrospectively examined in a specifically WD outpatient clinic in the İstanbul Faculty of Medicine. Results: A total of 131 pregnancies in 54 patients were examined. The mean age at diagnosis of WD was 22.1 ± 10.8 years. The mean follow-up period of patients diagnosed with WD was 87 ± 80 months. Forty (74.1%) patients were diagnosed with hepatic, 5 (9.3%) neurological, and 9 (16.6%) with mixed involvement WD. The liver was cirrhotic in 68 (51.9%) pregnancies. Ninety-eight (74.8%) preg nancies resulted in live birth, 30 spontaneous abortions (22.9%), and 3 (2.3%) stillbirths. Pregnancies diagnosed with mixed pattern WD had a lower live birth rate than those diagnosed with WD with isolated hepatic or neurological involvement (P < .001 and P = .004, respectively). While the spontaneous abortion rate decreases with WD treatment, the rate of live birth, stillbirth, premature birth, and low birth weight did not change in the total group. During pregnancy, patients used D-penicillamine, trientine, and/or zinc. Conclusion: With careful monitoring and management by medical professionals, pregnant women diagnosed with WD can still achieve successful pregnancies and improve their quality of life. Cite this article as: Demir K, Örmeci AÇ, Çavuş B, et al. Maternal and fetal outcomes of pregnancies in Wilson’s disease: A single centre real-life experience. Turk J Gastroenterol. Published online October 22, 2025. doi:10.5152/tjg.2025.25448.
- 22 October 2025
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Gastroenterology
- Vol. 37 (3) , 301-309
Open AccessMaternal and Fetal Outcomes of Pregnancies in Wilson’s Disease: A Single-Centre Real-Life Experience
Background/Aims: This study aims to investigate the fetal outcomes and pregnancy course in patients with Wilson’s disease (WD). Materials and Methods: A total of 54 female patients with a diagnosis of WD and a history of pregnancy between 1985 and 2021 were retrospectively examined in a specifically WD outpatient clinic in the İstanbul Faculty of Medicine. Results: A total of 131 pregnancies in 54 patients were examined. The mean age at diagnosis of WD was 22.1 ± 10.8 years. The mean follow-up period of patients diagnosed with WD was 87 ± 80 months. Forty (74.1%) patients were diagnosed with hepatic, 5 (9.3%) neurological, and 9 (16.6%) with mixed involvement WD. The liver was cirrhotic in 68 (51.9%) pregnancies. Ninety-eight (74.8%) preg nancies resulted in live birth, 30 spontaneous abortions (22.9%), and 3 (2.3%) stillbirths. Pregnancies diagnosed with mixed pattern WD had a lower live birth rate than those diagnosed with WD with isolated hepatic or neurological involvement (P < .001 and P = .004, respectively). While the spontaneous abortion rate decreases with WD treatment, the rate of live birth, stillbirth, premature birth, and low birth weight did not change in the total group. During pregnancy, patients used D-penicillamine, trientine, and/or zinc. Conclusion: With careful monitoring and management by medical professionals, pregnant women diagnosed with WD can still achieve successful pregnancies and improve their quality of life. Cite this article as: Demir K, Örmeci AÇ, Çavuş B, et al. Maternal and fetal outcomes of pregnancies in Wilson’s disease: A single centre real-life experience. Turk J Gastroenterol. Published online October 22, 2025. doi:10.5152/tjg.2025.25448.
- Open Access
- 15 August 2025
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 55 (4) , 846-854
What are the predictors of malignancy in inflammatory bowel disease?
Background/aimː This study aims to investigate the prevalence of malignancy in patients with inflammatory bowel disease (IBD) followed up in a tertiary reference center. Materials and methodsː IBD patients with at least 6 months of follow-up from the gastroenterology clinic between 2000 and 2022 wereevaluated retrospectively in a tertiary center. Patient information was obtained from the patient registration system. Resultsː There were 697 patients in the study, 320 (45.9%) of these were female. The mean age of the patients at IBD diagnosis was 33.4± 13.1 years. The mean follow-up time was 93.1 ± 64.8 (median 84, IQR (25–75) (36–144)) months. IBD types were as; 315 (45.2%) hadulcerative colitis, and 382 (54.8%) had Crohn’s disease. Before the diagnosis of IBD, 10 patients (1.4%) had a history of malignancy. Theprevalence of malignancy after the diagnosis of IBD was 13 (1.9%). There was a relationship between malignancy and older age, higherBMI, and female sex in survival analysis (p < 0.05). There was no correlation with disease type and malignancy (p = 0.820). When thepatients who developed malignancy in IBD were compared in terms of the immunomodulators and biological agents used by the patients who did not develop malignancy, there was no statistical difference between the two groups (p > 0.05). Conclusionː Older age, higher BMI, and female sex were found to be at risk for the development of malignancy in IBD, although norelationship was found with the use of immunomodulators, biological agents, or disease type.
- 15 August 2025
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 55 (4) , 846-854
Open AccessWhat are the predictors of malignancy in inflammatory bowel disease?
Background/aimː This study aims to investigate the prevalence of malignancy in patients with inflammatory bowel disease (IBD) followed up in a tertiary reference center. Materials and methodsː IBD patients with at least 6 months of follow-up from the gastroenterology clinic between 2000 and 2022 wereevaluated retrospectively in a tertiary center. Patient information was obtained from the patient registration system. Resultsː There were 697 patients in the study, 320 (45.9%) of these were female. The mean age of the patients at IBD diagnosis was 33.4± 13.1 years. The mean follow-up time was 93.1 ± 64.8 (median 84, IQR (25–75) (36–144)) months. IBD types were as; 315 (45.2%) hadulcerative colitis, and 382 (54.8%) had Crohn’s disease. Before the diagnosis of IBD, 10 patients (1.4%) had a history of malignancy. Theprevalence of malignancy after the diagnosis of IBD was 13 (1.9%). There was a relationship between malignancy and older age, higherBMI, and female sex in survival analysis (p < 0.05). There was no correlation with disease type and malignancy (p = 0.820). When thepatients who developed malignancy in IBD were compared in terms of the immunomodulators and biological agents used by the patients who did not develop malignancy, there was no statistical difference between the two groups (p > 0.05). Conclusionː Older age, higher BMI, and female sex were found to be at risk for the development of malignancy in IBD, although norelationship was found with the use of immunomodulators, biological agents, or disease type.
- 2 July 2025
- Published by Wiley in Transplant Infectious Disease
- Vol. 27 (5) , e70068
Real World Efficacy and Safety of Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Liver Transplant Recipients
Background: The efficacy and safety of nucleos(t)ide analogs is currently a critical issue in the treatment of hepatitis B virus infection. We aimed to investigate the long‐term efficacy and safety profile of tenofovir alafenamide (TAF) treatment in the liver transplant recipients (LTRs). Methods: This retrospective study was conducted with 72 LTRs who received TAF as sequential therapy after tenofovir disoproxil fumarate (TDF). The renal, metabolic outcomes, and efficacy of TAF were evaluated. In addition, some parameters were evaluated separately according to the use of calcineurin inhibitors. Results: Following TAF treatment, median serum phosphorus levels and estimated glomerular filtration rate (eGFR) increased significantly in the overall cohort (from 2.4 to 2.85 mg/dL [ p < 0.001]; from 66 to 74 mL/min/1.73 m 2 [ p = 0.028], respectively). These improvements were more pronounced in patients with baseline hypophosphatemia and reduced eGFR. However, no significant changes were observed in eGFR staging. A categorical worsening of lipid profile was noted based on the NCEP ATP‐III criteria, with increases in some lipid parameters. No significant weight gain or increase in the incidence of posttransplant diabetes mellitus was observed. Antiviral efficacy was maintained following the switch from TDF to TAF. In addition, no significant changes in immunosuppressive drug dosing were required, and no adverse events related to TAF were reported. Conclusion: TAF was well‐tolerated and effective in LTRs. The long‐term benefits of TAF on hypophosphatemia, renal function, and effective viral suppression were demonstrated. The patients with an increased risk of cardiovascular disease should receive more intensive monitoring for changes in their lipid profile.
- 2 July 2025
- Published by Wiley in Transplant Infectious Disease
- Vol. 27 (5) , e70068
Real World Efficacy and Safety of Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Liver Transplant Recipients
Background: The efficacy and safety of nucleos(t)ide analogs is currently a critical issue in the treatment of hepatitis B virus infection. We aimed to investigate the long‐term efficacy and safety profile of tenofovir alafenamide (TAF) treatment in the liver transplant recipients (LTRs). Methods: This retrospective study was conducted with 72 LTRs who received TAF as sequential therapy after tenofovir disoproxil fumarate (TDF). The renal, metabolic outcomes, and efficacy of TAF were evaluated. In addition, some parameters were evaluated separately according to the use of calcineurin inhibitors. Results: Following TAF treatment, median serum phosphorus levels and estimated glomerular filtration rate (eGFR) increased significantly in the overall cohort (from 2.4 to 2.85 mg/dL [ p < 0.001]; from 66 to 74 mL/min/1.73 m 2 [ p = 0.028], respectively). These improvements were more pronounced in patients with baseline hypophosphatemia and reduced eGFR. However, no significant changes were observed in eGFR staging. A categorical worsening of lipid profile was noted based on the NCEP ATP‐III criteria, with increases in some lipid parameters. No significant weight gain or increase in the incidence of posttransplant diabetes mellitus was observed. Antiviral efficacy was maintained following the switch from TDF to TAF. In addition, no significant changes in immunosuppressive drug dosing were required, and no adverse events related to TAF were reported. Conclusion: TAF was well‐tolerated and effective in LTRs. The long‐term benefits of TAF on hypophosphatemia, renal function, and effective viral suppression were demonstrated. The patients with an increased risk of cardiovascular disease should receive more intensive monitoring for changes in their lipid profile.
- Open Access
- 16 June 2025
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Gastroenterology
- Vol. 36 (7) , 467-473
The Role of Pancreatic Enzyme Insufficiency in the Etiology of Functional Dyspepsia Resistant to Standard Treatment
Background/Aims: Functional dyspepsia (FD) is diagnosed in the absence of an identifiable organic cause. Pancreatic enzyme insuf ficiency (PEI) remains an underrecognized condition in these patients. This study aimed to investigate the prevalence of PEI among FD patients unresponsive to standard therapy and to evaluate its clinical and biochemical characteristics. Materials and Methods: A total of 154 patients diagnosed with FD were followed, among which 66 patients who did not respond to at least 4 weeks of standard treatment, including acid-reducing therapies, prokinetics, and antidepressants, were evaluated. Additionally, 34 healthy volunteers were included as a control group. Organic pathologies were excluded in all 66 patients with FD resistant to stan dard treatment using endoscopy, endoscopic biopsy, and imaging methods. Fecal elastase-1 (FE-1) enzyme levels were measured to determine the prevalence of PEI in both groups. Results: Pancreatic enzyme insufficiency was detected in 5 (7.57%) of the 66 treatment-resistant FD patients, while none of the con trols had PEI. The prevalence of PEI was significantly higher in diabetic patients than in non-diabetic patients within the study group (P = .037). Patients with diarrhea, sticky stools, and frequent foul-smelling stools exhibited a higher prevalence of PEI (P = .022, P = .001, and P = .004, respectively). In the study group, PEI patients had lower serum calcium, phosphorus, and magnesium levels than the control group (P = .018, P = .011, and P = .001, respectively). Conclusion: Pancreatic enzyme insufficiency was identified in 7.57% of patients resistant to standard treatment. In patients resistant to standard therapy for at least 4 weeks, the presence of symptoms such as diarrhea, sticky stools, and foul-smelling stools, along with diabetes mellitus and low serum calcium, phosphorus, and magnesium levels, may warrant consideration of PEI as a potential underlying condition. Cite this article as: Kemik F, Ceylan G, Aydin AF, et al. The role of pancreatic enzyme insufficiency in the etiology of functional dyspepsia resistant to standard treatment. Turk J Gastroenterol. 2025;36(7):467-473.
- 16 June 2025
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Gastroenterology
- Vol. 36 (7) , 467-473
Open AccessThe Role of Pancreatic Enzyme Insufficiency in the Etiology of Functional Dyspepsia Resistant to Standard Treatment
Background/Aims: Functional dyspepsia (FD) is diagnosed in the absence of an identifiable organic cause. Pancreatic enzyme insuf ficiency (PEI) remains an underrecognized condition in these patients. This study aimed to investigate the prevalence of PEI among FD patients unresponsive to standard therapy and to evaluate its clinical and biochemical characteristics. Materials and Methods: A total of 154 patients diagnosed with FD were followed, among which 66 patients who did not respond to at least 4 weeks of standard treatment, including acid-reducing therapies, prokinetics, and antidepressants, were evaluated. Additionally, 34 healthy volunteers were included as a control group. Organic pathologies were excluded in all 66 patients with FD resistant to stan dard treatment using endoscopy, endoscopic biopsy, and imaging methods. Fecal elastase-1 (FE-1) enzyme levels were measured to determine the prevalence of PEI in both groups. Results: Pancreatic enzyme insufficiency was detected in 5 (7.57%) of the 66 treatment-resistant FD patients, while none of the con trols had PEI. The prevalence of PEI was significantly higher in diabetic patients than in non-diabetic patients within the study group (P = .037). Patients with diarrhea, sticky stools, and frequent foul-smelling stools exhibited a higher prevalence of PEI (P = .022, P = .001, and P = .004, respectively). In the study group, PEI patients had lower serum calcium, phosphorus, and magnesium levels than the control group (P = .018, P = .011, and P = .001, respectively). Conclusion: Pancreatic enzyme insufficiency was identified in 7.57% of patients resistant to standard treatment. In patients resistant to standard therapy for at least 4 weeks, the presence of symptoms such as diarrhea, sticky stools, and foul-smelling stools, along with diabetes mellitus and low serum calcium, phosphorus, and magnesium levels, may warrant consideration of PEI as a potential underlying condition. Cite this article as: Kemik F, Ceylan G, Aydin AF, et al. The role of pancreatic enzyme insufficiency in the etiology of functional dyspepsia resistant to standard treatment. Turk J Gastroenterol. 2025;36(7):467-473.
- Open Access
- 13 January 2025
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Gastroenterology
- Vol. 36 (6) , 390-397
Intra-Abdominal Hypertension and Its Prognostic Impact on Mortality in Cirrhotic Patients with Ascites: The Role of Paracentesis
Background/Aims: Elevated intra-abdominal pressure (IAP) can lead to intra-abdominal hypertension (IAH) and, in severe cases, abdominal compartment syndrome (ACS) in patients with cirrhosis and ascites. Paracentesis reduces IAP and improves abdominal perfusion. Intra-abdominal hypertension can also trigger acute-on-chronic liver failure (ACLF) in decompensated cirrhosis. This study evaluates the association between IAH and short-term mortality in patients with cirrhosis and ascites. Materials and Methods: This prospective, single-center cohort study included 18 patients (7 females, 11 males; median age: 59) sched uled for therapeutic paracentesis. Intra-abdominal pressure was measured using the bladder technique. Patients were grouped based on initial Chronic Liver Failure Consortium Organ Failure (CLIF-C OF) scores as ACLF or non-ACLF and followed up for 3 months. Results: The median model for end-stage liver disease score was 17 (IQR 11-19). The primary etiologies of cirrhosis were viral hepatitis and alcoholic liver disease. Independent risk factors for IAH included advanced liver disease and large-volume ascites. Pre paracentesis IAP was higher in ACLF patients (22 vs. 18 mm Hg). Post-paracentesis IAP was also higher in ACLF patients (14 vs. 8 mm Hg, P = .007). The 3-month mortality rate was 50%, with worse survival in ACLF patients (24 vs. 76.9 days, P = .002). Pre-paracentesis IAP was signifi cantly higher in patients who died (22 vs. 18 mm Hg, P = .034), and survival was worse in those with IAP #18.5 mm Hg (P = .026). Conclusion: Intra-abdominal pressure is elevated in cirrhosis patients with grade 3 ascites. Despite similar paracentesis volumes, IAP remained higher in the ACLF group. Intra-abdominal pressure #18.5 mm Hg is associated with significantly reduced survival, indicating that IAH accelerates short-term mortality in these patients. Cite this article as: Mutlu U, Genc Ulucecen S, Iliaz R, et al. Intra-abdominal hypertension and its prognostic impact on mortality in cirrhotic patients with ascites: The role of paracentesis. Turk J Gastroenterol. 2025;36(6):390-397.
- 13 January 2025
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Gastroenterology
- Vol. 36 (6) , 390-397
Open AccessIntra-Abdominal Hypertension and Its Prognostic Impact on Mortality in Cirrhotic Patients with Ascites: The Role of Paracentesis
Background/Aims: Elevated intra-abdominal pressure (IAP) can lead to intra-abdominal hypertension (IAH) and, in severe cases, abdominal compartment syndrome (ACS) in patients with cirrhosis and ascites. Paracentesis reduces IAP and improves abdominal perfusion. Intra-abdominal hypertension can also trigger acute-on-chronic liver failure (ACLF) in decompensated cirrhosis. This study evaluates the association between IAH and short-term mortality in patients with cirrhosis and ascites. Materials and Methods: This prospective, single-center cohort study included 18 patients (7 females, 11 males; median age: 59) sched uled for therapeutic paracentesis. Intra-abdominal pressure was measured using the bladder technique. Patients were grouped based on initial Chronic Liver Failure Consortium Organ Failure (CLIF-C OF) scores as ACLF or non-ACLF and followed up for 3 months. Results: The median model for end-stage liver disease score was 17 (IQR 11-19). The primary etiologies of cirrhosis were viral hepatitis and alcoholic liver disease. Independent risk factors for IAH included advanced liver disease and large-volume ascites. Pre paracentesis IAP was higher in ACLF patients (22 vs. 18 mm Hg). Post-paracentesis IAP was also higher in ACLF patients (14 vs. 8 mm Hg, P = .007). The 3-month mortality rate was 50%, with worse survival in ACLF patients (24 vs. 76.9 days, P = .002). Pre-paracentesis IAP was signifi cantly higher in patients who died (22 vs. 18 mm Hg, P = .034), and survival was worse in those with IAP #18.5 mm Hg (P = .026). Conclusion: Intra-abdominal pressure is elevated in cirrhosis patients with grade 3 ascites. Despite similar paracentesis volumes, IAP remained higher in the ACLF group. Intra-abdominal pressure #18.5 mm Hg is associated with significantly reduced survival, indicating that IAH accelerates short-term mortality in these patients. Cite this article as: Mutlu U, Genc Ulucecen S, Iliaz R, et al. Intra-abdominal hypertension and its prognostic impact on mortality in cirrhotic patients with ascites: The role of paracentesis. Turk J Gastroenterol. 2025;36(6):390-397.
- Open Access
- 11 January 2025
- Published by Oxford University Press (OUP) in Gastroenterology Report
- Vol. 13, goaf017
From chelation to transplantation: lessons from a progressive familial intrahepatic cholestasis type 3 case initially managed as Wilson’s disease
- 11 January 2025
- Published by Oxford University Press (OUP) in Gastroenterology Report
- Vol. 13, goaf017
Open AccessFrom chelation to transplantation: lessons from a progressive familial intrahepatic cholestasis type 3 case initially managed as Wilson’s disease
- Open Access
- 6 January 2025
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Gastroenterology
- Vol. 36 (4) , 219-228
Inflammation and Immune-Based Scores Predict Prognosis for Patients with Hepatocellular Carcinoma: A Pilot Single-Center Study
Background/Aims: Hepatocellular carcinoma (HCC) ranks as a major contributor to cancer-related deaths. Systemic inflammation plays a pivotal role in HCC development and progression. Thus, we aimed to determine the impact of inflammation- and immune-based scores in predicting the prognosis of HCC. Materials and Methods: In this retrospective study, patients with HCC were enrolled between 2010 and 2020. The purpose of this ret rospective study was to evaluate the impact of various biomarkers, including baseline alpha fetoprotein (AFP) levels, C-reactive protein (CRP) –albu min–l ympho cyte (CALLY) index, neutrophil-to-CRP (N/CRP) ratio, systemic immune-inflammation index (SII), albumin–bili rubin (ALBI) score, neutr ophil -to-l ympho cyte ratio (NLR), and aspartate aminotransferase (AST)-to-alanine aminotransferase (ALT) (AST/ALT) ratio (AAR), on survival, invasion of vascular tracts, metastasis, and treatment responses. Results: A total of 199 patients with complete (n = 44) and non-complete (n = 145) treatment response groups were enrolled in the study. All scores for the non-complete response group were statistically significant (P < .05). The areas under the curves for predicting a non-complete response group were 0.651, 0.649, 0.636, 0.625, 0.613, 0.609, and 0.600 for AFP, CALLY index, AAR, SII, N/CRP ratio, ALBI score, and NLR, respectively. These results are consistent with the assessment of mortality and HCC progression. Conclusion: Our results indicate that these biomarkers could serve as powerful prognostic tools for HCC. Cite this article as: Guzel Dirim M, Cifcibasi Ormeci A, Cavus B, et al. Inflammation and immune-based scores predict prognosis for patients with hepatocellular carcinoma: A pilot single-center study. Turk J Gastroenterol. 2025;36(4):219-228.
- 6 January 2025
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Gastroenterology
- Vol. 36 (4) , 219-228
Open AccessInflammation and Immune-Based Scores Predict Prognosis for Patients with Hepatocellular Carcinoma: A Pilot Single-Center Study
Background/Aims: Hepatocellular carcinoma (HCC) ranks as a major contributor to cancer-related deaths. Systemic inflammation plays a pivotal role in HCC development and progression. Thus, we aimed to determine the impact of inflammation- and immune-based scores in predicting the prognosis of HCC. Materials and Methods: In this retrospective study, patients with HCC were enrolled between 2010 and 2020. The purpose of this ret rospective study was to evaluate the impact of various biomarkers, including baseline alpha fetoprotein (AFP) levels, C-reactive protein (CRP) –albu min–l ympho cyte (CALLY) index, neutrophil-to-CRP (N/CRP) ratio, systemic immune-inflammation index (SII), albumin–bili rubin (ALBI) score, neutr ophil -to-l ympho cyte ratio (NLR), and aspartate aminotransferase (AST)-to-alanine aminotransferase (ALT) (AST/ALT) ratio (AAR), on survival, invasion of vascular tracts, metastasis, and treatment responses. Results: A total of 199 patients with complete (n = 44) and non-complete (n = 145) treatment response groups were enrolled in the study. All scores for the non-complete response group were statistically significant (P < .05). The areas under the curves for predicting a non-complete response group were 0.651, 0.649, 0.636, 0.625, 0.613, 0.609, and 0.600 for AFP, CALLY index, AAR, SII, N/CRP ratio, ALBI score, and NLR, respectively. These results are consistent with the assessment of mortality and HCC progression. Conclusion: Our results indicate that these biomarkers could serve as powerful prognostic tools for HCC. Cite this article as: Guzel Dirim M, Cifcibasi Ormeci A, Cavus B, et al. Inflammation and immune-based scores predict prognosis for patients with hepatocellular carcinoma: A pilot single-center study. Turk J Gastroenterol. 2025;36(4):219-228.
- Open Access
- 1 January 2025
- Published by Wiley in International Journal of Hepatology
- Vol. 2025 (1) , 9632839
Virological and Biochemical Effects of Tenofovir Alafenamide in Different Patient Groups With Chronic Hepatitis B Virus Infection in Real‐World Cohort
Hepatitis B virus (HBV) infection is an important health concern worldwide. HBV infection can lead to acute hepatitis, cirrhosis, hepatocellular carcinoma, liver failure, and death. Nucleos(t)ide analogs (NAs) form the core of the HBV treatment. The safety and efficacy of NAs in long‐term follow‐up are still critical issues. We enrolled 225 consecutive patients with at least 12 months of longitudinal follow‐up using tenofovir alafenamide (TAF), including 39 antiviral naïve and 186 antiviral experienced patients. In the treatment‐experienced group, the main reasons for switching from other NAs to TAF were renal dysfunction and osteoporosis. Renal outcome, lipid profile, virological response, and ALT normalization under the TAF treatment were evaluated. Age > 60 years, liver transplant recipients, and patients with decompensated cirrhosis were evaluated separately, as well as the total cohort. Phosphorus levels increased especially in hypophosphatemic individuals, eGFR levels also increased slightly but statistically significantly, and the remarkable improvement in eGFR stages was observed in the eGFR < 60 mL/min/1.73 m 2 group. A minimal increase in LDL‐c levels occurred after TAF treatment, which did not reach statistical significance. Total cholesterol and HDL‐c levels increased significantly, while triglyceride levels remained unchanged. In the total cohort, HBV‐DNA was strongly suppressed in either treatment‐naïve or experienced patients. ALT and AST levels decreased with the TAF treatment, but ALT normalization rate did not change significantly. No serious adverse events associated with TAF occurred, and discontinuation was not required in the total cohort. Our findings support that TAF treatment is well‐tolerated and effective in patients with chronic HBV infection.
- 1 January 2025
- Published by Wiley in International Journal of Hepatology
- Vol. 2025 (1) , 9632839
Open AccessVirological and Biochemical Effects of Tenofovir Alafenamide in Different Patient Groups With Chronic Hepatitis B Virus Infection in Real‐World Cohort
Hepatitis B virus (HBV) infection is an important health concern worldwide. HBV infection can lead to acute hepatitis, cirrhosis, hepatocellular carcinoma, liver failure, and death. Nucleos(t)ide analogs (NAs) form the core of the HBV treatment. The safety and efficacy of NAs in long‐term follow‐up are still critical issues. We enrolled 225 consecutive patients with at least 12 months of longitudinal follow‐up using tenofovir alafenamide (TAF), including 39 antiviral naïve and 186 antiviral experienced patients. In the treatment‐experienced group, the main reasons for switching from other NAs to TAF were renal dysfunction and osteoporosis. Renal outcome, lipid profile, virological response, and ALT normalization under the TAF treatment were evaluated. Age > 60 years, liver transplant recipients, and patients with decompensated cirrhosis were evaluated separately, as well as the total cohort. Phosphorus levels increased especially in hypophosphatemic individuals, eGFR levels also increased slightly but statistically significantly, and the remarkable improvement in eGFR stages was observed in the eGFR < 60 mL/min/1.73 m 2 group. A minimal increase in LDL‐c levels occurred after TAF treatment, which did not reach statistical significance. Total cholesterol and HDL‐c levels increased significantly, while triglyceride levels remained unchanged. In the total cohort, HBV‐DNA was strongly suppressed in either treatment‐naïve or experienced patients. ALT and AST levels decreased with the TAF treatment, but ALT normalization rate did not change significantly. No serious adverse events associated with TAF occurred, and discontinuation was not required in the total cohort. Our findings support that TAF treatment is well‐tolerated and effective in patients with chronic HBV infection.